Left Ventricular Assist Device Exchange Increases Heart Transplant Wait-List Mortality.

Heart transplantation Left ventricular assist device exchange Pump exchange Transplant candidate Ventricular assist device Waitlist mortality

Journal

The Journal of surgical research
ISSN: 1095-8673
Titre abrégé: J Surg Res
Pays: United States
ID NLM: 0376340

Informations de publication

Date de publication:
11 2020
Historique:
received: 01 02 2020
revised: 02 04 2020
accepted: 03 05 2020
pubmed: 23 6 2020
medline: 1 12 2020
entrez: 23 6 2020
Statut: ppublish

Résumé

The new heart transplant allocation criteria prioritize inpatients who require temporary mechanical circulatory support and give lower urgency to candidates on a durable left ventricular assist device (LVAD) who require a device exchange. This study explores whether the latter group should warrant higher priority to reduce wait-list mortality. This is a retrospective observational study of 13,113 adult heart transplant candidates in the Organ Procurement and Transplantation Network database who underwent LVAD implantation between 2007 and 2017. It evaluates the impact of LVAD exchange on the composite endpoint of death or removal from the wait list owing to worsening medical condition 1 y after device implantation. There were 1085 pump exchanges in 954 patients (7% of candidates), of which 22% were women. The pump exchange rate was 5.92 events per 100 patient-years. One-year survival was lower for those who required a pump exchange (76.3% versus 88.5%, logrank P < 0.001). This was congruent with the risk-adjusted mortality 1-y after implantation (hazards ratio: 2.56, 95% confidence interval: 2.18-3.00, P < 0.001). These findings indicate that among candidates awaiting heart transplantation with a durable LVAD, undergoing pump exchange doubles the risk of 1-y mortality. Giving priority to these candidates may reduce wait-list mortality.

Sections du résumé

BACKGROUND
The new heart transplant allocation criteria prioritize inpatients who require temporary mechanical circulatory support and give lower urgency to candidates on a durable left ventricular assist device (LVAD) who require a device exchange. This study explores whether the latter group should warrant higher priority to reduce wait-list mortality.
METHODS
This is a retrospective observational study of 13,113 adult heart transplant candidates in the Organ Procurement and Transplantation Network database who underwent LVAD implantation between 2007 and 2017. It evaluates the impact of LVAD exchange on the composite endpoint of death or removal from the wait list owing to worsening medical condition 1 y after device implantation.
RESULTS
There were 1085 pump exchanges in 954 patients (7% of candidates), of which 22% were women. The pump exchange rate was 5.92 events per 100 patient-years. One-year survival was lower for those who required a pump exchange (76.3% versus 88.5%, logrank P < 0.001). This was congruent with the risk-adjusted mortality 1-y after implantation (hazards ratio: 2.56, 95% confidence interval: 2.18-3.00, P < 0.001).
CONCLUSIONS
These findings indicate that among candidates awaiting heart transplantation with a durable LVAD, undergoing pump exchange doubles the risk of 1-y mortality. Giving priority to these candidates may reduce wait-list mortality.

Identifiants

pubmed: 32570131
pii: S0022-4804(20)30337-1
doi: 10.1016/j.jss.2020.05.062
pii:
doi:

Types de publication

Journal Article Observational Study Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

277-284

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Alejandro Suarez-Pierre (A)

Johns Hopkins University School of Medicine, Baltimore, Maryland. Electronic address: asuarez@jhmi.edu.

Eric Etchill (E)

Johns Hopkins University School of Medicine, Baltimore, Maryland.

Katherine Giuliano (K)

Johns Hopkins University School of Medicine, Baltimore, Maryland.

Cecillia Lui (C)

Johns Hopkins University School of Medicine, Baltimore, Maryland.

Charles D Fraser (CD)

Johns Hopkins University School of Medicine, Baltimore, Maryland.

Chun W Choi (CW)

Johns Hopkins University School of Medicine, Baltimore, Maryland.

Robert S Higgins (RS)

Johns Hopkins University School of Medicine, Baltimore, Maryland.

Ahmet Kilic (A)

Johns Hopkins University School of Medicine, Baltimore, Maryland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH